XML 17 R2.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Apr. 03, 2020
Jan. 03, 2020
Current assets:    
Cash and cash equivalents $ 357,340 $ 266,501
Short-term investments 597,028 585,742
Trade receivables, net 137,338 119,073
Inventory 15,417 12,886
Prepaid expenses and other current assets 29,773 26,988
Total current assets 1,136,896 1,011,190
Long-term investments 486,036 536,385
Property and equipment, net 48,489 48,892
Deferred tax assets, net 163,187 172,374
Goodwill 63,684 63,684
Other long-term assets 57,312 53,145
Total assets 1,955,604 1,885,670
Current liabilities:    
Accounts payable 15,321 11,581
Accrued compensation and benefits 26,687 37,364
Accrued clinical trial liabilities 34,969 38,777
Rebates and fees due to customers 23,006 18,719
Accrued collaboration liabilities 8,663 11,856
Other current liabilities 31,831 24,449
Total current liabilities 140,477 142,746
Long-term portion of deferred revenue 14,133 6,596
Long-term portion of operating lease liabilities 47,883 48,011
Other long-term liabilities 5,459 2,347
Total liabilities 207,952 199,700
Commitments
Stockholders’ equity:    
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 305,780 and 304,831 at March 31, 2020 and December 31, 2019, respectively 306 305
Additional paid-in capital 2,258,307 2,241,947
Accumulated other comprehensive income (loss) (222) 3,069
Accumulated deficit (510,739) (559,351)
Total stockholders’ equity 1,747,652 1,685,970
Total liabilities and stockholders’ equity $ 1,955,604 $ 1,885,670